At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 54 enrolled
Drug / intervention
AT-1501drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2a Open-Label, Multi-Center Study to Evaluate the Safety and Tolerability of Multiple Doses of AT-1501 in Adults With ALS
In Brief
A Phase 2 clinical trial evaluating AT-1501 for Amyotrophic Lateral Sclerosis. Completed, enrolled 54 participants across 13 sites in 2 countries.
Detailed Summary
This is a Phase 2a, multi-center, open label, multiple dose study of AT-1501, a humanized monoclonal antibody antagonist to CD40 ligand (CD40L). Approximately 54 adults with Amyotrophic Lateral Sclerosis (ALS) will be enrolled into the study in the United States and Canada at approximately 13 ALS treatment sites. Participants will be enrolled into one of four ascending doses.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAmyotrophic Lateral Sclerosis
CountriesCanada, United States
Collaborators--
Timeline
Phase 2CompletedFinished
202120222023202420252026
First PostedMar 2020
Enrollment StartOct 2020
Primary CompletionMar 2022
TodayJul 2026
First PostedMar 26, 2020
Enrollment StartOct 16, 2020
Primary CompletionMar 24, 2022
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 6.3 years ago
Interventions
AT-1501drug
AT-1501 monoclonal antibody targeting CD40L given as an IV infusion